Physician profile
Robert G Collum
NPI 1912941899
$2,301.07
in general payments reported to CMS, 2019-2025
30 companies · $809 in 2025
The $809 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.78 · 2020: $12.37 · 2022: $60.77 · 2023: $697 · 2024: $709 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $442.68 | 2023-2025 | Vraylar, Qulipta |
| Pfizer INC. | $403.37 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $219.05 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $200.53 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $144.90 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $130.63 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.37 | 2023-2025 | Jardiance, Synjardy |
| Becton, Dickinson and Company | $57.81 | 2024-2025 | Bd Max System, Bd Max Instrument, Bd Onclarity |
| Abbott Laboratories | $57.06 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $55.03 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $49.09 | 2025 | Capvaxive, Gardasil 9 |
| Amgen INC. | $48.63 | 2023-2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $41.36 | 2023 | Myrbetriq, Veozah |
| Alk-Abello, INC | $40.17 | 2025 | Neffy, Grastek, Odactra |
| Lundbeck LLC | $37.35 | 2025 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $32.86 | 2023-2025 | Kristalose |
| Exact Sciences Corporation | $28.84 | 2025 | Cologuard Collection Kit |
| W. L. Gore & Associates, INC. | $28.42 | 2024 | Gore Seamguard Bioabsorbable Staple Line Reinforce |
| Bayer Healthcare Pharmaceuticals INC. | $21.02 | 2023 | |
| Novartis Pharmaceuticals Corporation | $18.88 | 2022 | |
| Kyowa Kirin, INC. | $18.80 | 2024 | Crysvita |
| Renalytix Ai, INC. | $18.76 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Xeris Pharmaceuticals, INC. | $18.15 | 2023 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $17.00 | 2025 | Zoryve |
| Seqirus USA INC | $17.00 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Idorsia Pharmaceuticals US INC | $15.11 | 2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $14.43 | 2022 | |
| Ibsa Pharma INC. | $14.18 | 2023 | Tirosint, Licart |
| Takeda Pharmaceuticals U.S.A., INC. | $12.81 | 2023 | Gattex |
| Allergan, INC. | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Collum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.